Prior Authorization Creates Hurdle in Hepatitis C Treatment

BY JENNIFER G. ALLEN
Patient access to curative hepatitis C medications remains a challenge.
PUBLISHED MONDAY, MARCH 28, 2016
With the flood of curative medications for hepatitis C hitting the market, the cost of these drugs remains problematic for patient access to treatment.

Research published in PLoS ONE conducted a retrospective chart review of patients in Connecticut receiving sofosbuvir/ledipasvir (Harvoni) to see if the prior authorization (PA) process created a potential barrier to timely and effective care for hepatitis C virus (HCV) infection.

Authors noted that the treatment of HCV infection in the United States has been revolutionized by novel direct-acting antiviral (DAA) therapies. Compared with interferon-based therapies, DAA agents such as Harvoni have demonstrated better tolerability, adherence, rates of sustained virologic response, and cure rates. This advance, they said, has expanded the population of individuals with HCV infection who are potentially treatable.

The researchers add that the American Association for the Study of Liver Disease (AASLD) and the Infectious Disease Society of American (IDSA) have recognized the efficacy of Harvoni by including it as a recommended first-line therapy for HCV genotype-1 infection, the most prevalent strain in the United States.



The Hepatitis C Care Cascade



The concept of a care cascade first was applied to the treatment of patients with HIV as a means of identifying care gaps and setting goals in antiviral therapy. It represents the chain of necessary steps leading to therapeutic success: diagnosis, linkage to care, retention in care, prescription of antiretroviral therapy, and viral suppression. The care cascade has been adopted to identify barriers in the antiviral treatment of HIV, HCV–HIV co-infection, and most recently, HCV mono-infected individuals.

With the emergence of DAAs, prior authorization has become a crucial factor in the care cascade for HCV infection, the authors said. DAA therapy is very expensive, with a 12-week treatment course of Harvoni costing approximately $94,500, or $1125 per pill. The combination of prohibitive cost and limited availability means that PA guidelines often prioritize approval for patients with the highest need, usually defined as advanced fibrosis (≥ grade F3) or cirrhosis.

To determine how these conditions may impact the care cascade for all patients receiving Harvoni, their research objective was to look at PA approval rates for Harvoni over a 3-month period and try to identify factors associated with PA approval, time to PA decision, and time to PA approval.



What Predicts Prior Authorization Approval?



Investigators looked at the medical charts of all patients at Yale Liver Center who filed an insurance PA request for Harvoni between October 11, 2014 and December 31, 2014. Patients who received a prescription for HCV therapy other than Harvoni were excluded from the study, yielding a final sample of 129 individuals.

In addition to data on PA decisions and the timing of those decisions, researchers collected data on patient characteristics (age, race, body mass index, comorbid hypertension, psychiatric illness, diabetes, renal disease, hepatitis B, or HIV co-infection, and baseline biochemical markers), HCV viral characteristics (genotype, viral load, IL28B gene variant, and prior regimens), and severity of HCV infection (progression of hepatic fibrosis) as possible predictors.

Recommended Articles
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
Antiviral therapies are changing the clinical landscape for the treatment of HCV in developed countries.
$auto_registration$